Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) appointed veteran medical device engineer Dale Brady as Principal R&D Engineer, strengthening its product development organization for cardiorenal solutions. According to Nuwellis, Brady joins the research and development team to advance existing and new product development programs.
Brady brings more than 25 years of experience across R&D, operations, manufacturing, quality systems and commercialization. He has led multidisciplinary teams taking products from concept through regulatory submission, manufacturing scale-up and commercial launch at startups and public device companies, and is inventor or co-inventor on 10 issued U.S. patents and 16 pending applications.
Positive
- None.
Negative
- None.
Market Reaction – NUWE
Following this news, NUWE has declined 0.58%, reflecting a mild negative market reaction. Argus tracked a peak move of +8.8% during the session. Our momentum scanner has triggered 6 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.70.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 28 | Pediatric expansion | Positive | -3.0% | First Aquadex SmartFlow installations expanded Nuwellis' pediatric critical care footprint in Wisconsin. |
| Jul 27 | Revenue update | Positive | -2.9% | Preliminary second-quarter revenue growth reached 14% year over year. |
| Jul 16 | Patent award | Positive | -5.8% | The USPTO issued a patent covering Nuwellis' dual-lumen catheter technology. |
| Jul 07 | Therapy showcase | Positive | -4.3% | Nuwellis planned to showcase Aquadex therapy at the KidneyBee Summit. |
| Jun 26 | Conference support | Neutral | -0.3% | The company marked five years supporting the pediatric cardiac critical care consortium. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The five listed recent news events each had negative 24-hour reactions, including announcements involving expansion, revenue growth, patenting, and product showcasing.
Key Terms
regulatory submission regulatory
manufacturing scale-up technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Veteran medical device engineering leader brings more than 25 years of experience developing and commercializing innovative technologies from concept through market launch
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Dale Brady as Principal R&D Engineer. Brady brings more than 25 years of medical device leadership experience in research and development, operations, manufacturing, quality systems and commercialization, with a proven track record of advancing innovative products from concept through commercial launch. As Principal R&D Engineer, Brady joins Nuwellis’ research and development team to advance its existing and new product development programs.
"Dale's experience developing innovative medical technologies from concept through commercialization makes him an outstanding addition to our organization," said Mike McCormick, Nuwellis President and Chief Executive Officer. "As we continue to expand our product development pipeline and execute on multiple strategic initiatives, Dale brings the technical depth, operational discipline, and hands-on leadership that will help accelerate innovation while maintaining our focus on quality and execution."
Throughout Brady’s career, he has successfully led multidisciplinary engineering teams and developed products from initial concept through regulatory submission, manufacturing scale-up and commercial launch across both venture-backed startups and publicly traded medical device companies. Most recently, Brady served on the executive leadership teams of Peytant Solutions and Endogenex, where he directed engineering and operations activities supporting commercialization and clinical development.
Previously, Brady spent nearly a decade at Osprey Medical leading development of next-generation cardiovascular technologies and digital monitoring systems, and held engineering leadership positions at Anulex Technologies and Spine-Tech. He is also an inventor or co-inventor on 10 issued U.S. patents and 16 pending patent applications. Brady holds a Master of Science in Engineering Management from the University of Alaska Fairbanks and a Bachelor of Science in Mechanical Engineering from the University of Minnesota.
Kim Anderson, Nuwellis Vice President, Research & Development, Quality and Operations, added: "Dale is a tremendous addition to our engineering organization. He has a unique combination of deep technical expertise and practical experience leading product development in both entrepreneurial medical device companies and publicly traded organizations. He is an ideal fit for Nuwellis given his ability and expertise to advance products from concept through commercialization, while working effectively in resource-constrained environments. Dale will play a key role in leading many of our internal product development initiatives and strengthening our ability to execute multiple strategic programs simultaneously.”
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
CORE IR
ir@nuwellis.com
Media Contact:
CORE PR
media@nuwellis.com
